← Leaderboards
Linda J. Saif
Ohio State University
$10,776,838
Attributed
$16,706,463
Total exposure
15
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.2M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$27,084,719 · 16
By mechanism
R01$13,032,483 · 7
U54$12,235,836 · 4
R21$1,709,056 · 4
R03$107,344 · 1
Top collaborators
- Anastasia Nickolaevna Vlasova12 shared
- Ann Scheck Mcalearney6 shared
- Eugene M. Oltz6 shared
- Ashish Raman Panchal6 shared
- Terry L Bowlin5 shared
- Kyeong-Ok Chang5 shared
- William C Groutas5 shared
- Gireesh Rajashekara5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Anastasia Nickolaevna Vlasova$2,306,699
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusResponseInnovationImmuneAntibodiesImmune ResponseImmunityFamily SuidaeInfectionRotavirusRotavirus VaccinesViralCostMucosal ImmunityVaccinesChildOralImmunoglobulin AIntestinesDiarrheaCytokineGnotobioticAnimalsDeveloping Countries
Grant awards (52)
Center for serological testing to improve outcomes from pandemic COVID-19 (STOP-COVID)$846,715
U54 · FY2024 · CA
Rotavirus Reverse Genetics System to Study Viral Pathogenesis and Receptor Interactions$236,250
R21 · FY2024 · AI
Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)$3,143,795
U54 · FY2023 · CA
Rotavirus Reverse Genetics System to Study Viral Pathogenesis and Receptor Interactions$196,875
R21 · FY2023 · AI
Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)$1,995,256
U54 · FY2022 · CA
Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection$599,757
U54 · FY2022 · CA · contact PI
The impact of vitamin A on the gut-mammary gland-secretory IgA axis during enteric viral infections$460,503
R01 · FY2022 · HD · contact PI
Admin-Core-001$439,659
U54 · FY2022 · CA
Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)$439,659
U54 · FY2022 · CA
The impact of vitamin A on the gut-mammary gland-secretory IgA axis during enteric viral infections$460,503
R01 · FY2021 · HD · contact PI
Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP-COVID)$3,952,831
U54 · FY2020 · CA
Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection$818,164
U54 · FY2020 · CA · contact PI
The impact of vitamin A on the gut-mammary gland-secretory IgA axis during enteric viral infections$469,901
R01 · FY2020 · HD · contact PI
The impact of vitamin A on the gut-mammary gland-secretory IgA axis during enteric viral infections$446,963
R01 · FY2019 · HD · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2018 · AI
The impact of vitamin A on the gut-mammary gland-secretory IgA axis during enteric viral infections$446,963
R01 · FY2018 · HD · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2017 · AI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2016 · AI
Gut microflora: Impact on neonatal immunity, viral gastroenteritis and vaccines$515,000
R01 · FY2016 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$734,295
R01 · FY2015 · AI
Gut microflora: Impact on neonatal immunity, viral gastroenteritis and vaccines$415,000
R01 · FY2015 · AI · contact PI
Norovirus 3CL Protease-Based Anti-norovirus Therapeutics$784,022
R01 · FY2014 · AI
Gut microflora: Impact on neonatal immunity, viral gastroenteritis and vaccines$415,000
R01 · FY2014 · AI · contact PI
Gut microflora: Impact on neonatal immunity, viral gastroenteritis and vaccines$415,000
R01 · FY2013 · AI · contact PI
Gut microflora: Impact on neonatal immunity, viral gastroenteritis and vaccines$415,000
R01 · FY2012 · AI · contact PI
Lactogenic immunity/probiotics: Effect on neonatal gut immunity$187,500
R21 · FY2010 · AT · contact PI
Vitamin A adjuvant to enhance gut immunity and rotavirus vaccines in neonates$178,061
R21 · FY2010 · AI · contact PI
Lactogenic immunity/probiotics: Effect on neonatal gut immunity$61,723
R21 · FY2010 · AT · contact PI
Heterologous abs from llama and chicken egg yolk to prevent rotavirus diarrhea$33,840
R03 · FY2010 · TW · contact PI
Lactogenic immunity/probiotics: Effect on neonatal gut immunity$225,000
R21 · FY2009 · AT · contact PI
Vitamin A adjuvant to enhance gut immunity and rotavirus vaccines in neonates$217,792
R21 · FY2009 · AI · contact PI
Heterologous abs from llama and chicken egg yolk to prevent rotavirus diarrhea$33,840
R03 · FY2009 · TW · contact PI
Heterologous abs from llama and chicken egg yolk to prevent rotavirus diarrhea$39,664
R03 · FY2008 · TW · contact PI
Porcine Respiratory Coronavirus as a SARS Model$442,065
R01 · FY2007 · AI · contact PI
Porcine Respiratory Coronavirus as a SARS Model$472,183
R01 · FY2006 · AI · contact PI
Antigenic Relationships of SARS and Animal Coronaviruses$218,980
R21 · FY2006 · AI · contact PI
ENHANCING THE IMMUNOGENICITY OF HUMAN ROTAVIRUS VACCINES$216,051
R01 · FY2006 · AI · contact PI
Porcine Respiratory Coronavirus as a SARS Model$474,951
R01 · FY2005 · AI
ENHANCING THE IMMUNOGENICITY OF HUMAN ROTAVIRUS VACCINES$221,250
R01 · FY2005 · AI
Antigenic Relationships of SARS and Animal Coronaviruses$186,875
R21 · FY2005 · AI
Porcine Respiratory Coronavirus as a SARS Model$511,993
R01 · FY2004 · AI
ENHANCING THE IMMUNOGENICITY OF HUMAN ROTAVIRUS VACCINES$221,250
R01 · FY2004 · AI
PATHOGENESIS- HUMAN CALICIVIRUSES IN GNOTOBIOTIC ANIMALS$258,125
R01 · FY2003 · AI
IMMUNE RESPONSES TO ROTAVIRUS-- ROLE MATERNAL ANTIBODIES$221,250
R01 · FY2003 · AI
ENHANCING THE IMMUNOGENICITY OF HUMAN ROTAVIRUS VACCINES$110,625
R01 · FY2003 · AI
PATHOGENESIS- HUMAN CALICIVIRUSES IN GNOTOBIOTIC ANIMALS$232,313
R01 · FY2002 · AI
IMMUNE RESPONSES TO ROTAVIRUS-- ROLE MATERNAL ANTIBODIES$221,250
R01 · FY2002 · AI
PATHOGENESIS- HUMAN CALICIVIRUSES IN GNOTOBIOTIC ANIMALS$294,166
R01 · FY2001 · AI
IMMUNE RESPONSES TO ROTAVIRUS-- ROLE MATERNAL ANTIBODIES$240,967
R01 · FY2001 · AI
PATHOGENESIS- HUMAN CALICIVIRUSES IN GNOTOBIOTIC ANIMALS$284,600
R01 · FY2000 · AI
IMMUNE RESPONSES TO ROTAVIRUS-- ROLE MATERNAL ANTIBODIES$252,413
R01 · FY2000 · AI
ENHANCING THE IMMUNOGENICITY OF HUMAN ROTAVIRUS VACCINES$175,996
R01 · FY2000 · AI